KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Sales and Divestitures: 2012-2017

  • Neogenomics' Gains from Sales and Divestitures rose 452.38% to $182,744 in Q4 2017 from the same period last year, while for Dec 2017 it was $182,744, marking a year-over-year increase of 452.38%. This contributed to the annual value of $182,744 for FY2017, which is 452.38% up from last year.
  • Neogenomics' Gains from Sales and Divestitures amounted to $182,744 in Q4 2017, which was up 452.38% from $33,083 recorded in Q4 2016.
  • In the past 5 years, Neogenomics' Gains from Sales and Divestitures ranged from a high of $182,744 in Q4 2017 and a low of $12,820 during Q4 2015.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $33,083 (2016), whereas its average is $76,216.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 43.36% in 2014, then soared by 452.38% in 2017.
  • Quarterly analysis of 5 years shows Neogenomics' Gains from Sales and Divestitures stood at $32,000 in 2013, then tumbled by 43.36% to $18,125 in 2014, then dropped by 29.27% to $12,820 in 2015, then spiked by 158.06% to $33,083 in 2016, then surged by 452.38% to $182,744 in 2017.
  • Its last three reported values are $182,744 in Q4 2017, $33,083 for Q4 2016, and $12,820 during Q4 2015.